샘플 요청 목록

 카트 문의
시장보고서
상품코드
1588962

세계의 소마토스타틴 유사체 시장

Somatostatin Analogs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 94 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

소마토스타틴 유사체 세계 시장은 2030년까지 124억 달러에 달할 것으로 전망

2023년 84억 달러로 추정되는 소마토스타틴 유사체 세계 시장은 2023-2030년 분석 기간 동안 연평균 5.8% 성장하여 2030년에는 124억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 옥트레오타이드는 CAGR 4.8%를 기록하여 분석 기간 종료 시점에 50억 달러에 도달할 것으로 예상됩니다. 파실레오티드 분야의 성장률은 분석 기간 동안 CAGR 6.8%로 추정됩니다.

미국 시장 22억 달러로 추정, 중국은 CAGR 8.8%로 성장 전망

미국의 소마토스타틴 유사체 시장은 2023년 22억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2023-2030년 분석 기간 동안 8.8%의 CAGR을 기록하며 2030년에는 28억 달러 규모에 달할 것으로 예측됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 3.0%와 5.2%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 연평균 3.4%의 성장률을 보일 것으로 예상됩니다.

세계 소마토스타틴 유사체 시장 - 주요 동향 및 촉진요인 요약

소마토스타틴 유사체는 호르몬 장애 치료에 어떤 혁명을 일으키고 있는가?

소마토스타틴 유사체는 성장호르몬, 인슐린, 글루카곤 등 여러 호르몬의 분비를 억제하는 호르몬인 소마토스타틴의 작용을 모방한 합성 화합물입니다. 이러한 유사 화합물은 말단 비대증, 신경내분비종양, 특정 소화기 질환과 같은 호르몬 질환의 치료에 널리 사용되고 있습니다. 옥트레오타이드, 란레오타이드, 파실레오타이드와 같은 소마토스타틴 유사체는 호르몬 관련 질환을 관리하고 증상을 완화하며 환자의 예후를 개선하는 효과적인 치료 옵션을 제공합니다. 내분비 질환에 대한 연구가 진행됨에 따라 KEYWORD는 현대 의학에 필수적인 요소가 되어 더 나은 질병 관리와 환자 치료를 지원하고 있습니다.

소마토스타틴 유사체 시장의 주요 부문은?

주요 약물 유형에는 옥트레오타이드, 란레오타이드, 파실레오타이드 등이 있으며, 말단거대증과 신경내분비종양 치료에 널리 사용되는 옥트레오타이드가 가장 큰 시장 점유율을 차지하고 있습니다. 응용 분야에는 말단거대증, 신경내분비종양, 소화관 출혈이 포함되며, 신경내분비종양은 이러한 질환의 진단 및 인지도가 높아짐에 따라 중요한 부문을 차지하고 있습니다. 판매 채널에는 병원, 소매 약국, 전문 클리닉 등이 있으며, 소마토스타틴 유사체를 효과적으로 관리해야 하는 복잡한 환자를 치료하는 병원이 시장을 주도하고 있습니다.

소마토스타틴 유사체는 어떻게 치료에 사용됩니까?

첨단 거대증에서 소마토스타틴 유사체는 성장호르몬의 과도한 분비를 억제하여 신체 비대 및 대사 장애와 같은 증상을 조절합니다. 신경내분비종양의 경우, 이러한 유사 약물은 호르몬 분비를 억제하고 안면 홍조, 설사 등의 증상을 완화하고 종양의 성장을 지연시킵니다. 소화관 출혈의 경우, 소마토스타틴 유사체는 환부로 가는 혈류를 감소시켜 응급 치료와 안정화를 돕습니다. 또한 소마토스타틴 유사체는 특정 신경내분비종양의 영상 진단에 사용되어 발견 및 치료 계획을 강화합니다.

소마토스타틴 유사체 시장의 성장을 촉진하는 요인은 무엇인가?

소마토스타틴 유사체 시장의 성장은 말단거대증 및 신경내분비종양과 같이 효과적인 장기 관리가 필요한 호르몬 질환의 유병률 증가 등 여러 요인에 의해 주도되고 있습니다. 서방형 및 주사제를 포함한 약물 제형의 발전은 환자의 복약 순응도와 치료 결과를 향상시켜 보다 폭넓은 채택을 촉진하고 있습니다. 표적 치료와 맞춤 의료에 대한 관심은 호르몬 관련 질환에 대한 특이적이고 효과적인 치료 옵션을 제공하는 소마토스타틴 유사체에 대한 수요를 더욱 촉진하고 있습니다. 또한, 의료비 지출 증가와 진단 시설의 개선으로 더 많은 환자들이 정확한 진단과 적시에 치료를 받을 수 있게 됨에 따라 시장 성장에 기여하고 있습니다.

조사 대상 기업 사례(주목 43개사)

  • Camurus AB
  • Chiasma Inc.
  • Crinetics Pharmaceuticals
  • Dauntless Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Novartis AG
  • Peptron, Inc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Inc

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.11.18

Global Somatostatin Analogs Market to Reach US$12.4 Billion by 2030

The global market for Somatostatin Analogs estimated at US$8.4 Billion in the year 2023, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Octreotide, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$5.0 Billion by the end of the analysis period. Growth in the Pasireotide segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 8.8% CAGR

The Somatostatin Analogs market in the U.S. is estimated at US$2.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Somatostatin Analogs Market - Key Trends and Drivers Summarized

How Are Somatostatin Analogs Revolutionizing Hormonal Disorders Treatment?

Somatostatin analogs are synthetic compounds that mimic the action of somatostatin, a hormone that inhibits the secretion of several other hormones, including growth hormone, insulin, and glucagon. These analogs are widely used in treating hormonal disorders like acromegaly, neuroendocrine tumors, and certain gastrointestinal conditions. Somatostatin analogs, such as octreotide, lanreotide, and pasireotide, offer effective therapeutic options for managing hormone-related diseases, reducing symptoms, and improving patient outcomes. As research in endocrine disorders advances, somatostatin analogs have become essential in modern medicine, supporting better disease management and patient care.

What Are the Key Segments in the Somatostatin Analogs Market?

Major drug types include octreotide, lanreotide, and pasireotide, with octreotide holding the largest market share due to its extensive use in treating acromegaly and neuroendocrine tumors. Applications cover acromegaly, neuroendocrine tumors, and gastrointestinal bleeding, with neuroendocrine tumors representing a significant segment driven by the increasing diagnosis and awareness of these conditions. Distribution channels include hospitals, retail pharmacies, and specialty clinics, with hospitals leading the market as they handle complex cases that require somatostatin analogs for effective management.

How Are Somatostatin Analogs Used Across Medical Treatments?

In acromegaly, somatostatin analogs inhibit the excessive release of growth hormone, controlling symptoms like enlarged body parts and metabolic disturbances. For neuroendocrine tumors, these analogs reduce hormone secretion, alleviating symptoms like flushing and diarrhea while slowing tumor growth. In cases of gastrointestinal bleeding, somatostatin analogs help reduce blood flow to affected areas, supporting emergency treatment and stabilization. Additionally, somatostatin analogs are used in diagnostic imaging for certain neuroendocrine tumors, enhancing detection and treatment planning.

What Factors Are Driving the Growth in the Somatostatin Analogs Market?

The growth in the Somatostatin Analogs market is driven by several factors, including increasing prevalence of hormonal disorders like acromegaly and neuroendocrine tumors, which require effective long-term management. Advancements in drug formulations, including extended-release and injectable versions, have improved patient adherence and outcomes, supporting broader adoption. The focus on targeted therapies and personalized medicine has further fueled demand, as somatostatin analogs offer specific and effective treatment options for hormone-related diseases. Additionally, rising healthcare expenditure and better diagnostic facilities have contributed to market growth, as more patients receive accurate diagnoses and timely treatment.

Select Competitors (Total 43 Featured) -

  • Camurus AB
  • Chiasma Inc.
  • Crinetics Pharmaceuticals
  • Dauntless Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Novartis AG
  • Peptron, Inc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Inc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Somatostatin Analogs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Neuroendocrine Tumors Drives Demand for Somatostatin Analogs
    • Rising Use in Acromegaly and Hormonal Disorders Spurs Market Growth
    • Technological Advancements in Long-Acting and Depot Formulations Propel Adoption
    • Growing Focus on Novel Drug Delivery Mechanisms Strengthens Business Case
    • Rising Adoption in Gastroenterology for Treating Variceal Bleeding Expands Opportunities
    • Growing Demand in Oncology as an Adjunct Treatment Expands Addressable Market
    • Rising Awareness of Rare Diseases Drives Adoption in Specialty Care
    • Emergence of Biosimilar Somatostatin Analogs Expands Market Opportunities
    • Increasing Focus on Personalized Medicine in Hormonal Disorders Propels Growth
    • Rising Use in Diagnostic Imaging for Neuroendocrine Tumors Spurs Demand
    • Growing Use in Palliative Care and Chronic Disease Management Drives Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Octreotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Octreotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Octreotide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Pasireotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Pasireotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Pasireotide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Lanreotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Lanreotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Lanreotide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Acromegaly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Acromegaly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Acromegaly by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neuroendocrine Tumors (NETs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Neuroendocrine Tumors (NETs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Neuroendocrine Tumors (NETs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Somatostatin Analogs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Somatostatin Analogs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Somatostatin Analogs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Somatostatin Analogs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Somatostatin Analogs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Somatostatin Analogs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Somatostatin Analogs by Type - Octreotide, Pasireotide and Lanreotide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Somatostatin Analogs by Type - Percentage Breakdown of Value Sales for Octreotide, Pasireotide and Lanreotide for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Somatostatin Analogs by Application - Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Somatostatin Analogs by Application - Percentage Breakdown of Value Sales for Acromegaly, Neuroendocrine Tumors (NETs) and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제